<DOC>
	<DOCNO>NCT01826006</DOCNO>
	<brief_summary>The occurrence no-reflow phenomenon recanalization infarct relate artery acute myocardial infarction describe 40 % case . This event associate bad prognosis follow unfavourable leave ventricular remodelling . Two main pathogenetic mechanism cause no-reflow : distal embolization , ischemia-reperfusion injury individual susceptibility . In context , Excimer Laser ( EL ) may play important role order reduce rate microvascular obstruction . Thus , randomize study assess effect EL versus Manual Thrombus Aspiration ST elevation MI use ST segment resolution standard 12 lead ECG primary endpoint myocardial reperfusion .</brief_summary>
	<brief_title>THE LASER-AMI STUDY - Excimer Laser Versus Manual Thrombus Aspiration Acute Myocardial Infarction</brief_title>
	<detailed_description>Acute myocardial infarction ( AMI ) lead cause death develop country . In patient AMI , prompt reopen occluded coronary artery main goal reperfusion therapy order restore normal blood flow myocardium , thus prevent leave ventricular ( LV ) adverse remodelling occurrence heart failure . Primary percutaneous coronary intervention ( PPCI ) represent pivotal step current management ST-segment elevation myocardial infarction ( STEMI ) ( 1 ) . Yet , sizable proportion patient , PPCI achieve epicardial coronary artery reperfusion myocardial reperfusion , condition know no-reflow ( 2 ) , increase extent myocardial damage . The proportion patient get optimal myocardial reperfusion , among without cardiogenic shock undergo PPCI , 35 % ( 3 ) . Thus , prevalence no-reflow remain extremely high . Furthermore , series consistent data clearly show no-reflow strong negative impact outcome , negate potential benefit PPCI ( 4-10 ) . Indeed , compare patient without no-reflow , patient no-reflow exhibit high prevalence : 1 ) early post-infarction complication ( arrhythmia , pericardial effusion , cardiac tamponade , early congestive heart failure ) ; 2 ) LV adverse remodelling ; 3 ) late re-hospitalizations heart failure ; 4 ) mortality . In man , no-reflow cause variable combination four pathogenetic mechanism : 1 ) distal atherothrombotic embolization , 2 ) ischemic injury , 3 ) reperfusion injury , 4 ) susceptibility coronary microcirculation injury ( 3 ) . As consequence , appropriately design strategy prevent treat , right time , component expect reduce final number patient no-reflow . Manual thrombus aspiration ( MTA ) clearly show improve microvascular perfusion survival STEMI patient treat PPCI ( 9,10 ) . Accordingly , current guideline European Society Cardiology ( ESC ) , MTA 2a recommendation ( 1 ) . Yet , complete ST-segment resolution ( define &gt; 70 % ) obtain 50 % patient ( 3,6 ) , thus suggest microvascular perfusion may improve . In context , Excimer laser ( EL ) may play important role order reduce rate microvascular obstruction . Coronary laser device emit electromagnetic energy , upon absorption within atherosclerotic plaque , debulk target tissue ( 11-12 ) . Over past decade , second generation pulsed-wave laser introduce ( 13 ) . These device combine brief pulse duration light emission long pause interval , thus ensure prevention thermal injury adverse effect arterial wall laser . The pulsed wave EL ( 308 nm , ultraviolet wavelength , UVB region spectrum ) FDA EMEA approve device treatment atherosclerotic coronary lesion consider `` non ideal '' standard balloon angioplasty ( 14-16 ) . Furthermore , continuous saline flush saline laser advancement allow reduce heat generation tissue damage . Taken together device improvement technical advancement allow low procedural complication rate confirm publish registry safety EL assist angioplasty ( 17-18 ) . In set thrombotic lesion , EL potential vaporize thrombotic plaque material , lead particle small size erythrocyte unlikely plug microcirculation ( 19-20 ) , inhibit platelet aggregation , induce platelet stun ( 21 ) . Furthermore , laser able debulk underlie thrombogenic plaque thus limit thrombogenicity ( 22 ) . EL use set STEMI within registry ( 23-26 ) small randomize trial v balloon assist PPCI ( 27 ) , show low rate myocardial no-reflow , assessed angiography ( around 5 % ) electrocardiography ( around 35 % ) . These study , however , limit small sample size non-randomized design . Thus , randomize study EL assist PPCI become necessary order evaluate efficacy mechanical strategy STEMI patient . As MTA-assisted PPCI nowadays recommend approach current guideline , effectiveness EL-assisted PPCI evaluate MTA-assisted PPCI . The goal trial , carry patient STEMI undergo PPCI , assess superiority EL-assisted vs MTA-assisted PPCI , primary end-point rate 90-min ST segment resolution &gt; 70 % secondary end-points rate angiographic no-reflow , defined TIMI flow3 MBG &gt; =2 ( 28 ) , evaluation infarct size , assess area curve cardiac marker ( 29 ) rate adverse remodelling assess echocardiography 6 month follow-up Description LASER-AMI trial Study design LASER-AMI randomized , open-label , blind-examination ( PROBE ) , active control , multinational clinical trial . Patients undergo PPCI randomly assign 1 2 interventional strategy reperfusion : MTA-assisted PPCI alone EL-assisted PPCI alone . Study protocol procedure The informed consent sign angiography . The randomization process start completion diagnostic angiography patient allocate one follow two arm : MTA-assisted PPCI alone ; EL-assisted PPCI alone . A consecutively number seal envelope open knowledge randomization arm . Each enrol center receive promote center exact number number envelope use randomization . The interventional procedure carry accord usual site 's local protocol . The choice vascular access stent type leave operator discretion . All patient receive aspirin per o ( 150-325 mg ) , clopidogrel ( 600 mg ) prasugrel ticagrelor emergency department . Anticoagulant therapy catheterization laboratory leave operator 's choice accord recent ESC guideline ( 1 ) ; GP IIb/IIIa inhibitor consider bailout therapy angiographic evidence massive thrombus , slow no-reﬂow thrombotic complication . After identification culprit vessel cross lesion guidewire , vessel recanalization start use either MTA EL , accord randomization ( see appendix 1 advice ELCA use ) . The choice MTA device leave site 's usual availability . Complications relate either ELCA MTA record ( perforation , dissection ) well failure restore antegrade flow lack cross culprit stenosis . The use balloon MTA EL leave operator discretion , even direct stenting recommend . In patient , MTA ELCA , intracoronary adenosine ( 120 µg fast bolus follow 2 mg give 33cc saline 2 minute slow bolus ) administer . Vessel recanalization complete coronary stenting . Postdilatation stent leave operator 's discretion , although stent overexpansion recommend order reduce risk no-reflow . Angiographic electrocardiography analysis Angiographic analysis perform off-line angio core lab ( IsMeTT , Palermo , Italy ) include : quantitative coronary angiography ( 31 ) , TIMI flow ( 32 ) , correct TIMI frame count ( 33 ) , MBG ( 34 ) , combine evaluation TIMI flow MBG ( 27 ) , thrombus score ( 35 ) , Rentrop collateral grading ( 36 ) . Angiographic no-reflow define final TIMI flow &lt; 2 final TIMI flow 3 MBG 0/1 ( 3,27 ) . These parameter assess accord validate method ( 31-36 ) . At 90 minute end procedure 12 lead ECG record analysis ST-segment resolution compare admission ECG . Complete ST-segment resolution define &gt; 70 % ST-segment compare baseline single lead show maximum ST-elevation admission sum lead show ST-elevation admission ( 37,38 ) Baseline ECG also assess off-line number Q wave terminal distorsion QRS ( 39 ) . ECG analysis perform offline ECG core lab ( Clinica di Cardiologia , UNIVPM , Ancona , Italy ) . Echocardiographic protocol At day 3 5 6-month index procedure patient undergo comprehensive 2D transthoracic echocardiography examination rest . End-systolic ( LVESV ) end-diastolic volume ( LVEDV ) , LV ejection fraction ( LVEF ) , presence degree mitral insufficiency wall motion score index ( segment score 1= normal/ hyperkinetic , 4 = dyskinetic , 16 segment model leave ventricle ) calculate follow recommendation American Society Echocardiography ( 40 ) . LV volumes ejection fraction measure modified biplane Simpson 's method , adjust body surface area . LV remodel defined increase end-diastolic volume &gt; 20 % 6 month AMI compare in-hospital examination ( 7 ) . Serious Adverse Events Serious adverse event record define untoward medical occurrence result cardiac death , vascular death , death , re-infarction , target lesion revascularization , target vessel revascularization , stent thrombosis . They communicate Safety Board within 24hours occurrence . Blood sample Blood sample collect PCI 4 , 8 , 12 , 24 , 36 , 48 , 72 h procedure measure creatine kinase-myocardial band ( CK-MB ) ( mass ) , troponin-T ( mass ) , hemoglobin level . Clinical follow-up The incidence cardiac death , myocardial infarction , target lesion revascularization heart failure require hospitalization assess 6 month interview clinical check 1 year telephone contact . In line protocol , interviewers examiner know drug administrate time procedure . The accumulation end-points define major adverse cardiac event ( MACEs ) . Study end-point The end-point study comparison rate ST-segment resolution 90 minute post PPCI patient randomize MTA-assisted PPCI EL-assisted PPCI . Thus , study test whether EL-assisted PPCI superior MTA-assisted PPCI reduce incidence electrocardiographic no-flow performing PPCI . Secondary endpoint : ) angiographic no-reflow defined TIMI flow ≤2 TIMI flow 3 MBG 0/1 ; b ) LVESV , LVEDV , LVEF , WMSI assess in-hospital 6 month echocardiography ; c ) infarct size , define CK-MB troponin-I area curve ; ) MACEs rate two group 6 1 year follow-up . Power calculation LASER-AMI randomize , open-label clinical trial , patient randomly assign 1 2 interventional strategy ( MTA-assisted PPCI ; EL-assisted PPCI ) . The primary objective LASER-AMI trial test superiority EL-assisted PPCI v MTA-assisted PPCI base rate post-procedural STR &gt; 70 % PPCI . The study sample size powered demonstrate significant difference primary end point rate STR &gt; 70 % , around 56 % previous trial PPCI MTA ( 10 ) . Starting figure thus assume 76 % event rate control group absolute 20 % decrease experimental group , calculate 194 patient ( 97 per group ) enrol alpha error 0.05 power 0.80 prospective 1:1 randomize study . Statistical analysis All analyse plan conducted accord intention-to-treat principle , approach minimizes risk selection bias alpha error . Continuous variable ( present mean ± standard deviation ) compare Student test normally distribute variable Wilcoxon test nonnormally distribute variable . Chi-square test use compare discrete variable ( report raw number [ % ] ) . Odds ratio ( OR ) 95 % confidence interval ( CI ) calculate compare event rate EL-assisted PPCI group versus observe MTA-assisted PPCI group ( consider control group ) . A multivariable logistic regression analysis also perform assess confirm independent predictive value randomization EL-assisted PPCI achievement STR &gt; 70 % ( cut-off entry 0.05 , cut-off removal 0.10 ) . Moreover , infarct size assessment perfomed , define CK-MB troponin-I area curve , calculate linear trapezoidal method ( 29 ) . If baseline 72-h value miss , value set 0 , whereas miss intermediate value substitute linear interpolation . For patient die first 72 h enrollment , area curve set large area curve record study ( 29 ) . Analyses carry use SPSS Windows 11.0 ( SPSS Inc. , Chicago , Illinois ) . Statistical significance define two-tailed p &lt; 0.05 . In addition , prespecified subgroup analysis mean multiple logistic regression multiple linear regression , appropriate , perform accord follow variable : age class , sex , diabetes , anterior myocardial infarction , total ischemic time cutoff , pre-infarction angina , baseline angiographic thrombus score , baseline TIMI flow , number diseased vessel .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Onset symptom MI le 12 hour prior enrolment ; STsegment elevation least 2 mm two contiguous lead ; Vessel lesion amenable coronary laser manual trhombus aspiration ( lack mark vessel/lesion tortuosity calcification ; reference vessel diameter &gt; 2.5 mm diameter ) ; Written inform consent . Rescue angioplasty fail thrombolysis ; Stent thrombosis ; Culprit lesion locate bypass graft leave main trunk ; Cardiogenic shock ; Young age ( &lt; 18 year ) ; Severe renal failure ( creatinine clearance ≤30 ml/min ) ; Concomitant disease result life expectancy le 6 month ; Pregnancy ; Contraindications contrast agent manageable medically , study medication , include aspirin , clopidogrel , ticlopidine heparin ; Left bundle branch block , pace rhythm , frequent ventricular ectopy , preexcitation ECG abnormalities interfere analysis STsegment resolution ; Markedly depress LV function ( LVEF &lt; 30 % ) ; Culprit lesion identify ; Severe leave main triple vessel disease require CABG index hospitalization ; Patients already involved ongoing trial ; Patients unable unwilling give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Myocardial Infarction</keyword>
	<keyword>No-reflow</keyword>
	<keyword>Primary PCI</keyword>
	<keyword>Coronary no-reflow phenomenon</keyword>
	<keyword>Primary percoutaneous coronary intervention ( primary PCI )</keyword>
</DOC>